Invitae Corporation (NYSE:NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced ...

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, has partnered with Invitae Corp., a leading medical genetics company, to expand education ...

This week, Invitae put out a press release highlighting the insights Praxis Precision Medicines was getting from Invitae's Citizen platform. The platform enables companies to get medical history data ...

SEATTLE, July 22, 2021 /PRNewswire/ — Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed ...

SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a ...

A little more than two years after California genetics-testing company Invitae Corp. (NYSE: NVTA) bought ArcherDX Inc., a Boulder developer of genetic assays for cancer patients, for $1.4 billion, ...

Invitae Corporation (NYSE: NVTA), which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence. The stock closed at $2.30 ...

Hi, everyone. Good afternoon. Thanks for joining us here. If you don't know me, my name is Andrew Brackmann, I cover diagnostics for William Blair. This afternoon, we have Invitae joining us. We have ...

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. Advanced medical genetics company ...

Invitae has high short interest, estimated at 17.2%. The Federal Reserve just raised interest rates, making it tougher for companies like Invitae to raise cash. Invitae is burning tons of cash right ...

Invitae reported that revenue grew 17.5%, year over year. The stock is still down more than 64% this year. Invitae said it has enough cash to last it through 2024. The company's second-quarter numbers ...